Literature DB >> 19060601

Seasons of survivorship revisited.

Kenneth Miller1, Brian Merry, Joan Miller.   

Abstract

Several decades ago the chance of a cancer survivor enjoying long-term survival was limited. At that time the terms cancer survivor and cancer survivorship were new. A cancer survivor was defined as a person from the moment of diagnosis onward for as long as they live. Cancer survivorship was also described in several "seasons" including; acute survivorship (the experience of diagnosis and treatment), extended survivorship (a time for "watchful waiting"), and then permanent survivorship (long-term remission). Today, acute cancer survivorship is still a time of intense emotion and medical activity surrounding the diagnosis, staging, and actual treatment. We then propose that after the intense initial therapy is completed the survivors enter a "season" that can be called "transitional cancer survivorship" reflecting the transition from active treatment to careful observation and the emotional, social, and medical adaptations that occur. Next, there are a growing number of cancer survivors who are (1) alive and "living with cancer" but requiring ongoing treatment for recurrent, active, and often advanced disease; (2) in a complete remission that requires ongoing therapy; or (3) in a complete remission and with a favorable prognosis. Collectively, this is a diverse group in "extended survivorship" and some later go on to obtain a permanent remission although others experience disease progression. Finally, there are millions of long-term or "permanent survivors." This group is also very heterogeneous and is comprised of 4 subgroups including (1) survivors who are "cancer-free but not free of cancer," (2) survivors who are cancer-free but continue to have significant "fall-out" from cancer and its treatment including psychosocial, medical, financial, or legal sequelae, (3) survivors who go on to develop second cancers which may be unrelated to the first cancer or its treatment, or may be more likely due to genetic or environmental factors, and also (4) survivors who later develop cancers that are secondary to the initial treatment.

Entities:  

Mesh:

Year:  2008        PMID: 19060601     DOI: 10.1097/PPO.0b013e31818edf60

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  18 in total

1.  What does the term 'survivor' mean to individuals diagnosed with a haematological malignancy? Findings from Australia.

Authors:  Pam McGrath; Hamish Holewa
Journal:  Support Care Cancer       Date:  2012-05-02       Impact factor: 3.603

2.  Translation and validation of tools for assessing health-related quality of life and male sexual function in Hong Kong Chinese patients during transitional cancer survivorship.

Authors:  Ka Ming Chow; Carmen W H Chan; Winnie K W So; Doris Y P Leung
Journal:  Support Care Cancer       Date:  2017-02-17       Impact factor: 3.603

3.  An exploratory study of the factors that influence physical activity for prostate cancer survivors.

Authors:  Melinda J Craike; Patricia M Livingston; Mari Botti
Journal:  Support Care Cancer       Date:  2010-07-10       Impact factor: 3.603

4.  Adaptation of the illness trajectory framework to describe the work of transitional cancer survivorship.

Authors:  Rachel Klimmek; Jennifer Wenzel
Journal:  Oncol Nurs Forum       Date:  2012-11       Impact factor: 2.172

5.  Patient perceptions of communications on the threshold of cancer survivorship: implications for provider responses.

Authors:  Sally E Thorne; Kelli I Stajduhar
Journal:  J Cancer Surviv       Date:  2012-03-20       Impact factor: 4.442

6.  Exploring the experience of recurrence with advanced cancer for people who perceived themselves to be cancer free: a grounded theory study.

Authors:  Denice Economou; Catherine Walshe; Sarah G Brearley
Journal:  Support Care Cancer       Date:  2021-01-02       Impact factor: 3.603

Review 7.  Who Is a Cancer Survivor? A Systematic Review of Published Definitions.

Authors:  Chiara Marzorati; Silvia Riva; Gabriella Pravettoni
Journal:  J Cancer Educ       Date:  2017-06       Impact factor: 2.037

8.  A framework for understanding cancer comparative effectiveness research data needs.

Authors:  William R Carpenter; Anne-Marie Meyer; Amy P Abernethy; Til Stürmer; Michael R Kosorok
Journal:  J Clin Epidemiol       Date:  2012-11       Impact factor: 6.437

Review 9.  Self-advocacy and cancer: a concept analysis.

Authors:  Teresa L Hagan; Heidi S Donovan
Journal:  J Adv Nurs       Date:  2013-01-24       Impact factor: 3.187

10.  Use of the word "cure" in oncology.

Authors:  Kenneth Miller; Joseph H Abraham; Lori Rhodes; Rachel Roberts
Journal:  J Oncol Pract       Date:  2013-03-12       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.